Frontier Biotechnologies
A commercial-stage bio-pharmaceutical company.
Launch date
Employees
Market cap
$242m
Enterprise valuation
$186m (Public information from Sep 2024)
Share price
CNY4.61 688221.SS
Nanjing Jiangsu (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 20.9m | 46.6m | 40.5m | 84.7m | 114m | 2.2b | 4.0b |
| % growth | - | 124 % | (13 %) | 109 % | 35 % | 1868 % | 79 % |
| EBITDA | (130m) | (192m) | (222m) | (298m) | (268m) | - | - |
| % EBITDA margin | (624 %) | (412 %) | (549 %) | (352 %) | (234 %) | - | - |
| Profit | (192m) | (231m) | (260m) | (357m) | (329m) | - | - |
| % profit margin | (923 %) | (495 %) | (642 %) | (421 %) | (288 %) | - | - |
| EV / revenue | - | 111.2x | 135.8x | 64.9x | 27.6x | - | - |
| EV / EBITDA | - | -27.0x | -24.7x | -18.5x | -11.8x | - | - |
| R&D budget | 85.4m | 138m | 172m | 274m | 214m | - | - |
| R&D % of revenue | 409 % | 297 % | 425 % | 324 % | 188 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Series A | |
* | N/A | N/A | Series B |
JPY300m | Series C | ||
| N/A | N/A | Early VC | |
* | N/A | N/A | Growth Equity VC |
| N/A | N/A | IPO | |
* | $29.0m | Private Placement VC | |
| Total Funding | $31.3m | ||
Recent News about Frontier Biotechnologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.